Show simple item record

dc.creatorBENOT DOMINGUEZ, REYES
dc.creatorCimini, Annamaria
dc.creatorBarone, Daniela
dc.creatorGiordano, Antonio
dc.creatorPentimalli, Francesca
dc.date.accessioned2024-01-23T15:32:21Z
dc.date.available2024-01-23T15:32:21Z
dc.date.issued2022-05-30
dc.identifier.citationBenot-Dominguez, R.; Cimini, A.; Barone, D.; Giordano, A.; Pentimalli, F. The Emerging Role of Cyclin-Dependent Kinase Inhibitors in Treating Diet-Induced Obesity: New Opportunities for Breast and Ovarian Cancers? Cancers 2022, 14, 2709. https://doi.org/10.3390/cancers14112709
dc.identifier.issn2072-6694
dc.identifier.urihttp://hdl.handle.net/20.500.12613/9636
dc.description.abstractOverweight and obesity constitute the most impactful lifestyle-dependent risk factors for cancer and have been tightly linked to a higher number of tumor-related deaths nowadays. The excessive accumulation of energy can lead to an imbalance in the level of essential cellular biomolecules that may result in inflammation and cell-cycle dysregulation. Nutritional strategies and phytochemicals are gaining interest in the management of obesity-related cancers, with several ongoing and completed clinical studies that support their effectiveness. At the same time, cyclin-dependent kinases (CDKs) are becoming an important target in breast and ovarian cancer treatment, with various FDA-approved CDK4/6 inhibitors that have recently received more attention for their potential role in diet-induced obesity (DIO). Here we provide an overview of the most recent studies involving nutraceuticals and other dietary strategies affecting cell-cycle pathways, which might impact the management of breast and ovarian cancers, as well as the repurposing of already commercialized chemotherapeutic options to treat DIO.
dc.format.extent25 pages
dc.languageEnglish
dc.language.isoeng
dc.relation.ispartofFaculty/ Researcher Works
dc.relation.haspartCancers, Vol. 14, Iss. 11
dc.relation.isreferencedbyMDPI
dc.rightsAttribution CC BY
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectCDK inhibitors (CDKIs)
dc.subjectDiet-induced obesity (DIO)
dc.subjectOvarian cancer
dc.subjectBreast cancer
dc.subjectCell-cycle inhibitors
dc.subjectRB1
dc.subjectCDK4/6
dc.titleThe Emerging Role of Cyclin-Dependent Kinase Inhibitors in Treating Diet-Induced Obesity: New Opportunities for Breast and Ovarian Cancers?
dc.typeText
dc.type.genreJournal article
dc.contributor.groupSbarro Health Organization (SBHO) (Temple University)
dc.description.departmentBiology
dc.relation.doihttp://dx.doi.org/10.3390/cancers14112709
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
dc.description.schoolcollegeTemple University. College of Science and Technology
dc.creator.orcidBenot-Dominguez|0000-0003-1256-9870
dc.creator.orcidGiordano|0000-0002-5959-016X
dc.temple.creatorBenot-Dominguez, Reyes
dc.temple.creatorGiordano, Antonio
refterms.dateFOA2024-01-23T15:32:22Z


Files in this item

Thumbnail
Name:
Benot-DominguezEtAl-JournalArt ...
Size:
1.025Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY